---
title: "AX: Q4 and FY26 delivered strong earnings growth, improved asset quality, and robust capital ratios"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294410214.md"
description: "Net income and EPS saw double-digit year-over-year growth in Q4 and full-year 2026, driven by strong loan and deposit growth, successful acquisitions, and robust non-interest income. Asset quality improved, and capital ratios remained strong.Original document: Axos Financial, Inc. [AX] SEC 8-K Current Report — Jul. 30 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-30T20:17:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294410214.md)
  - [en](https://longbridge.com/en/news/294410214.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294410214.md)
generator: "portal-rs"
---

# AX: Q4 and FY26 delivered strong earnings growth, improved asset quality, and robust capital ratios

Net income and EPS saw double-digit year-over-year growth in Q4 and full-year 2026, driven by strong loan and deposit growth, successful acquisitions, and robust non-interest income. Asset quality improved, and capital ratios remained strong.

Original document: Axos Financial, Inc. \[AX\] SEC 8-K Current Report — Jul. 30 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [AX.US](https://longbridge.com/en/quote/AX.US.md)

## Related News & Research

- [Is Axos Financial (AX) Undervalued Following Its Recent Pullback?](https://longbridge.com/en/news/296191457.md)
- [Axos net income rises 13.27% to $490.37 million in FY26](https://longbridge.com/en/news/296530665.md)
- [3 Next-Gen AI Stocks That 3G Capital Bought in Q2](https://longbridge.com/en/news/296496173.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**